comprehensive -WSS

comprehensive

author：focus 2025-09-06 03:54:41 - browse：75137

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Russians and Belarusians back at Wimbledon as war in Ukraine continues

focus

WSS

Greece's new parliament sworn in following conservative party's election victory

Elon Musk announces 'temporary limits' for reading Twitter posts

Readout LOUD podcast: possible new ALS drug, artificial wombs

FDA panel to weigh approval of NurOwn, controversial ALS drug

Changes to biosimilar regulatory framework must prioritize patients

US judge blocks portions of new Florida elections law

knowledge

comprehensive

explore

At least 13 dead in Texas as scorching temps continue

Why are Kaiser Permanente staff considering a strike?

Alkermes shareholders re

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

Novavax promises a turnaround & Lilly roils the obesity market

STAT Virtual Event: Putting AI to the Test

United colonoscopy coverage change 'may cost lives,' doctors say

How AI helped researchers track recovery from depression

At least 13 dead in Texas as scorching temps continue

Medical student insurance fails on mental health care coverage

explore

Churchill Downs extends trainer Bob Baffert's ban through 2024

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

Russians and Belarusians back at Wimbledon as war in Ukraine continues

CDC advisers recommend seasonal use of Pfizer RSV shot

Microbiome research is starting to find links to chronic diseases

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

hotspot

focus

focus

Wikipedia